[go: up one dir, main page]

NO20001196L - Nootropisk middel - Google Patents

Nootropisk middel

Info

Publication number
NO20001196L
NO20001196L NO20001196A NO20001196A NO20001196L NO 20001196 L NO20001196 L NO 20001196L NO 20001196 A NO20001196 A NO 20001196A NO 20001196 A NO20001196 A NO 20001196A NO 20001196 L NO20001196 L NO 20001196L
Authority
NO
Norway
Prior art keywords
long
activation
cerebral
term activation
nootropic agent
Prior art date
Application number
NO20001196A
Other languages
English (en)
Other versions
NO20001196D0 (no
Inventor
Tomoyuki Nishizaki
Mitsunobu Yoshii
Shigeo Watabe
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO20001196D0 publication Critical patent/NO20001196D0/no
Publication of NO20001196L publication Critical patent/NO20001196L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives et medikament som forbedrer cerebral neurotransmisjon basert på interaksjon mellom langtidsaktivering av en proteinkinase C-aktiveringsvei og langtidaktivering av presynaptiske nikotiniske acetylkolin- (nACh) reseptorer, og på en ledsagende økning av mengden frigitt glutamat, som aktiverer cerebral neuro- transmisjon over et lengre tidsrom. Substansene tjener som utmerkede nootropiske midler. De er særlig egnet til behandling av demens forårsaket av hydrokefali eller av subdural blødning.
NO20001196A 1997-09-12 2000-03-08 Nootropisk middel NO20001196L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9249131A JPH1180027A (ja) 1997-09-12 1997-09-12 向知性薬
PCT/JP1998/004136 WO1999013911A1 (en) 1997-09-12 1998-09-14 Nootropic agent

Publications (2)

Publication Number Publication Date
NO20001196D0 NO20001196D0 (no) 2000-03-08
NO20001196L true NO20001196L (no) 2000-05-10

Family

ID=17188397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001196A NO20001196L (no) 1997-09-12 2000-03-08 Nootropisk middel

Country Status (11)

Country Link
EP (1) EP1022029A1 (no)
JP (1) JPH1180027A (no)
KR (1) KR20010030582A (no)
CN (1) CN1270528A (no)
AU (1) AU9003598A (no)
BR (1) BR9815370A (no)
CA (1) CA2301782A1 (no)
ID (1) ID24282A (no)
IL (1) IL134661A0 (no)
NO (1) NO20001196L (no)
WO (1) WO1999013911A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544311B (en) * 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
KR20020015321A (ko) * 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
GB0021885D0 (en) * 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
CA2457982C (en) * 2001-08-22 2009-11-03 Daiichi Pharmaceutical Co., Ltd. Use of nefiracetam for treating neurodegeneration
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SI2889033T1 (en) 2008-11-19 2018-08-31 Forum Pharmaceuticals Inc. Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CN103221411B (zh) 2010-05-17 2016-05-11 富瑞姆制药公司 (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
JP6066312B2 (ja) * 2013-03-29 2017-01-25 国立研究開発法人理化学研究所 細胞膜片を備えた発電素子および発電デバイス

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923134B (en) * 1991-05-02 1993-01-27 Daiichi Seiyaku Co Agent for improving dementia
JP3388778B2 (ja) * 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
JPH06279311A (ja) * 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤

Also Published As

Publication number Publication date
EP1022029A1 (en) 2000-07-26
ID24282A (id) 2000-07-13
NO20001196D0 (no) 2000-03-08
JPH1180027A (ja) 1999-03-23
KR20010030582A (ko) 2001-04-16
CN1270528A (zh) 2000-10-18
BR9815370A (pt) 2000-10-24
AU9003598A (en) 1999-04-05
IL134661A0 (en) 2001-04-30
CA2301782A1 (en) 1999-03-25
WO1999013911A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
NO20001196L (no) Nootropisk middel
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
ATE234092T1 (de) 2-alkylpyrrolidine
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
FI905531A0 (fi) Transdermalisk anvaendning av 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobensotiazol.
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
NO20010446L (no) Substituert anilidforbindelser og metoder
DK0740650T3 (da) Codrugs som metode til styret transport af lægemiddel
FI963294A0 (fi) Naftyyliamidit keskushermostoaineina
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
DK0825857T3 (da) Anvendelse af gabapentin og derivater deraf til behandling af mani og bipolær lidelse
DK0520200T3 (da) Imadazol-forbindelser, deres fremstilling og anvendelse
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
FR2663326B2 (fr) Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
NO20005332L (no) 1,6-GPS-(6-O-α-D-glukopyranosyl-D-sorbit) og 1,1-GPM-(1-O-α-D-glukopyranosyl-D-mannit)-holdig sukkeralkoholblanding for bruk som terapeutisk aktivt stoff samt legemiddel inneholdende nevnte blanding
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
DK0914043T3 (da) Implanterbare agarose-kollagen-korn, som indeholder celler, der dannet et diffunderbart produkt, og anvendelser heraf
BR9915460A (pt) Método de tratamento de febre hemorrágica virótica
ATE201823T1 (de) Topische pharmazeutische zusammensetzungen, welche heparin enthalten
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
WO2001085165A3 (de) Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application